Calidi Biotherapeutics to Present RedTail Platform Data at 2026 ASCO Meeting
Event summary
- Two abstracts on Calidi's RedTail platform accepted for online publication at the 2026 ASCO Annual Meeting (May 29–June 2).
- Preclinical data for CLD-401 and CLD-501 to be presented, targeting tumor microenvironment remodeling.
- CLD-401 IND filing expected by year-end 2026.
- RedTail platform designed for systemic delivery of genetic medicines to metastatic sites.
The big picture
Calidi's ASCO presentation underscores the growing interest in systemic virotherapies for solid tumors, particularly in overcoming resistance to existing immunotherapies. The RedTail platform's ability to deliver genetic payloads to metastatic sites positions it within the competitive landscape of next-generation oncology treatments. Success hinges on demonstrating clinical utility beyond preclinical models.
What we're watching
- Clinical Translation
- Whether preclinical efficacy of CLD-401 and CLD-501 will translate into human trials.
- Regulatory Momentum
- The pace at which Calidi advances toward IND filing and potential Phase 1 trials.
- Partnership Strategy
- How strategic collaborations may accelerate RedTail platform development.
Related topics